RKDA - Arcadia Biosciences Inc Stock Price, Fair Value and News

3.05USD-0.22 (-6.73%)Market Closed

Market Summary

USD3.05-0.22

Market Closed

-6.73%

RKDA Stock Price

View Fullscreen

RKDA RSI Chart

RKDA Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.59

Price/Sales (Trailing)

0.79

EV/EBITDA

-0.22

Price/Free Cashflow

-0.28

RKDA Price/Sales (Trailing)

RKDA Profitability

EBT Margin

-87.78%

Return on Equity

-66.99%

Return on Assets

-43.76%

Free Cashflow Yield

-362.12%

RKDA Fundamentals

RKDA Revenue

Revenue (TTM)

5.2M

Rev. Growth (Yr)

-16.83%

Rev. Growth (Qtr)

25.19%

RKDA Earnings

Earnings (TTM)

-7.0M

Earnings Growth (Yr)

74.18%

Earnings Growth (Qtr)

15%

Breaking Down RKDA Revenue

Last 7 days

48.1%

Last 30 days

50.2%

Last 90 days

7.0%

Trailing 12 Months

-33.6%

How does RKDA drawdown profile look like?

RKDA Financial Health

Current Ratio

4.05

RKDA Investor Care

Shares Dilution (1Y)

43.40%

Diluted EPS (TTM)

-13.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.2M	0	0	0
2023	7.7M	5.2M	5.2M	5.5M
2022	9.1M	11.5M	10.7M	9.4M
2021	3.5M	4.6M	5.7M	6.8M
2020	1.3M	1.4M	1.3M	2.4M
2019	1.4M	1.2M	1.2M	1.2M
2018	3.2M	2.7M	2.4M	1.5M
2017	3.4M	3.6M	3.1M	4.0M
2016	5.5M	4.7M	4.0M	3.2M
2015	6.4M	6.5M	6.9M	5.4M
2014	0	0	0	7.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcadia Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	schaefer thomas j.	bought	1,442	2.06	700	chief financial officer
Aug 04, 2023	schaefer thomas j.	bought	2,381	3.67	649	chief financial officer
May 30, 2023	jacot stanley jr	bought	21,550	4.31	5,000	chief executive officer
Feb 01, 2023	schaefer thomas j.	bought	161	0.23	700	chief financial officer
Aug 01, 2022	haley pamela	bought	490	0.7	700	chief financial officer
Aug 03, 2020	shultz randall	bought	2,212	3.16	700	chief technology officer
Aug 03, 2020	haley pamela	bought	2,212	3.16	700	chief financial officer
Aug 03, 2020	plavan matthew t	bought	1,848	3.16	585	chief executive officer
Feb 03, 2020	plavan matthew t	bought	1,204	1.72	700	chief executive officer
Feb 03, 2020	reiter sarah	bought	1,204	1.72	700	chief commercial officer

Which funds bought or sold RKDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-10,445	26,357	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-191	457	-%
May 15, 2024	OLIVER LAGORE VANVALIN INVESTMENT GROUP	unchanged	-	-4.00	9.00	-%
May 15, 2024	SABBY MANAGEMENT, LLC	reduced	-58.58	-215,502,000	89,063,000	0.05%
May 15, 2024	Tower Research Capital LLC (TRC)	added	31.04	-673	8,341	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 13, 2024	UBS Group AG	new	-	4.00	4.00	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	23,000	23,000	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	-12,915	31,024	-%
May 10, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-16.00	39.00	-%

Are Funds Buying or Selling RKDA?

Are funds buying RKDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RKDA

No. of Funds

Unveiling Arcadia Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	58,315	SC 13G/A
Jan 03, 2024	sabby management, llc	8.76%	97,305	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	2,675,409	SC 13G
Jan 20, 2023	moral compass corp	4.6%	1,125,769	SC 13D/A
Feb 11, 2022	intracoastal capital, llc	4.6%	1,058,559	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	3.86%	890,049	SC 13G/A
Feb 10, 2021	hudson bay capital management lp	6.21%	890,049	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	5.3%	745,324	SC 13G/A
Feb 14, 2020	d. e. shaw & co, l.p.	0.2%	13,478	SC 13G/A
Feb 14, 2020	anson funds management lp	2.7%	236,766	SC 13G/A

Recent SEC filings of Arcadia Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 16, 2024	DEFA14A	DEFA14A
May 16, 2024	DEF 14A	DEF 14A
May 13, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	8-K	Current Report

Peers (Alternatives to Arcadia Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ADM	30.5B	91.7B	1.99%	-15.35%	10.02	0.33	-10.07%	-31.73%
BG	15.0B	61.3B	-2.21%	16.07%	7.7	0.25	-8.91%	30.43%
CAG	14.7B	12.1B	1.62%	-14.16%	15.43	1.21	-0.78%	18.26%
CPB	13.8B	9.3B	7.27%	-12.09%	18.08	1.49	1.02%	-5.78%
ACI	11.9B	79.2B	0.88%	1.68%	9.19	0.15	2.05%	-14.37%
MID-CAP
BRBR	7.5B	1.8B	5.71%	59.23%	39.11	4.06	23.06%	29.48%
FRPT	6.1B	823.2M	20.41%	92.18%	627.36	7.45	30.53%	114.65%
FLO	5.2B	5.1B	4.80%	-15.22%	41.05	1.01	4.66%	-41.11%
CENT	3.0B	3.3B	17.04%	57.25%	20.35	0.91	1.49%	31.18%
CALM	2.8B	2.4B	-3.61%	21.31%	10.29	1.19	-22.17%	-63.60%
SMALL-CAP
ANDE	1.8B	13.6B	-9.19%	34.04%	14.42	0.13	-21.14%	9.65%
BGS	743.1M	2.0B	-11.49%	-26.60%	-6.76	0.37	-5.45%	-247.51%
BYND	467.2M	326.7M	11.98%	-36.95%	-1.4	1.43	-18.66%	-2.70%
ALCO	208.0M	103.1M	2.36%	17.74%	5.21	2.02	56.46%	236.17%
AQB	7.1M	2.6M	5.71%	277.55%	-0.22	2.8	-0.77%	-36.97%

Arcadia Biosciences Inc News

Latest updates

Arcadia Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	25.2%	1,255,000	1,002,500	1,597,000	1,389,000	1,509,000	744,000	1,570,000	3,858,000	3,220,000	2,047,500	2,376,000	1,860,500	1,345,000	829,500	314,000	281,000	309,000	416,000	392,000	203,000	158,000
Costs and Expenses	5.0%	4,319,000	4,113,000	4,839,000	5,180,000	5,557,000	2,891,000	5,561,000	7,641,000	7,843,000	15,975,000	11,089,000	9,088,000	6,154,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	11,089,000	9,088,000	6,154,000	-339,000	7,895,000	7,157,000	6,099,000	4,404,500	6,585,000	5,185,000	4,376,000
S&GA Expenses	1.5%	3,189,000	3,140,500	3,443,000	3,815,000	4,392,000	2,743,000	4,178,000	4,652,000	4,349,000	6,196,000	6,312,000	6,370,000	4,069,000	4,778,000	4,292,000	3,674,000	3,723,000	3,132,500	4,477,000	3,146,000	2,812,000
R&D Expenses	-18.1%	272,000	332,000	305,000	391,000	359,000	500,000	255,000	359,000	395,000	561,000	1,038,000	1,131,000	1,159,000	1,961,000	1,762,000	1,993,000	2,244,000	1,711,500	1,931,000	1,950,000	1,505,000
EBITDA Margin	-9.3%	-0.72	-0.66	-1.46	-3.03	-2.07	-1.71	-2.04	-2.09	-2.62	-3.51	-4.18	-5.17	-6.82	-9.98	-	-	-	-	-	-	-
Interest Expenses	-71.3%	45,000	157,000	133,000	207,000	198,000	165,500	95,000	30,000	-1,000	-5,000	-15,000	-1,000	9,000	15,000	23,000	6,000	3,000	2,000	3,000	-	-
Income Taxes	-100.0%	-	7,000	-	1,000	-	13,000	1,000	-	-	1,000	1,000	-	-	-139,500	9,000	-10,000	17,000	-12,500	-3,000	-1,000	19,000
Earnings Before Taxes	100.0%	-	-2,616,000	-2,484,000	-	-	2,784,500	-2,287,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-4.8%	-0.88	-0.84	-1.65	-3.22	-2.18	-1.79	-2.11	-2.15	-2.71	-3.65	-4.35	-5.38	-7.06	-10.26	-	-	-	-	-	-	-
Net Income	15.0%	-2,423,000	-2,850,500	-2,567,000	818,000	-9,384,000	-4,173,000	-2,867,000	-3,797,000	-4,610,000	-8,744,000	-2,175,000	-5,422,000	1,681,000	9,052,000	-6,391,000	-9,893,000	2,423,000	-6,243,000	-14,187,000	4,237,000	-12,612,000
Net Income Margin	47.3%	-1.34	-2.54	-2.92	-2.99	-2.63	-1.64	-1.87	-1.68	-2.29	-2.16	0.55	-0.23	-1.58	-1.99	-	-	-	-	-	-	-
Free Cashflow	22.6%	-3,213,000	-4,151,000	-2,849,000	-4,839,000	-3,466,000	-2,382,000	-3,371,000	-3,371,000	-4,925,000	-6,748,000	-8,474,000	-6,461,000	-5,192,000	-7,048,000	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-18.6%	16,046	19,705	23,466	26,798	30,410	28,922	34,474	35,008	38,799	43,918	59,228	70,798	70,800	47,348	33,877	37,778	32,248	32,574	37,302	25,346	21,950
Current Assets	-22.2%	11,642	14,972	20,006	23,339	27,205	25,398	30,031	30,058	31,499	35,388	43,834	50,916	56,613	31,696	21,194	26,096	23,758	28,440	33,606	22,000	18,565
Cash Equivalents	-49.1%	3,317	6,518	10,611	13,500	22,998	20,644	22,719	21,234	24,600	28,685	35,526	44,000	32,848	14,042	10,201	14,995	12,973	8,417	20,541	14,646	10,438
Inventory	-6.5%	1,831	1,958	2,657	3,164	2,591	2,321	3,342	3,275	3,235	4,433	5,447	3,897	2,663	3,812	9,416	8,772	5,971	1,794	1,843	839	187
Net PPE	-14.6%	328	384	468	560	622	680	848	954	1,468	2,291	2,634	3,740	3,480	3,539	3,484	3,403	2,540	1,799	1,283	639	460
Goodwill	-	-	-	-	-	-	-	-	-	-	1,240	1,648	1,648	408	408	301	-	-	-	-	-	-
Liabilities	-20.6%	5,563	7,002	8,068	9,068	13,718	8,022	9,455	8,240	8,557	12,722	19,005	28,119	25,097	18,796	21,875	24,162	20,025	24,248	23,069	17,060	21,317
Current Liabilities	-19.8%	2,878	3,590	3,885	4,091	4,097	4,209	4,051	4,740	4,809	5,040	6,489	7,651	5,617	6,314	8,408	8,364	5,808	5,708	6,023	4,157	2,968
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	78.00	87.00	96.00	2,100	2,548	2,742	-	107	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	78.00	87.00	96.00	2,100	2,548	2,742	-	107	-	-	-
Shareholder's Equity	-18.4%	10,483	12,841	15,536	17,730	16,692	21,033	25,019	26,768	30,242	31,196	40,223	42,678	45,703	28,552	12,002	13,617	12,223	8,325	14,233	13,542	633
Retained Earnings	-0.9%	-274,300	-271,840	-268,987	-266,420	-267,243	-257,859	-253,615	-250,748	-246,971	-226,485	-217,200	-215,027	-209,767	-211,825	-220,725	-214,335	-204,646	-207,171	-200,928	-186,741	-190,978
Additional Paid-In Capital	0.1%	284,658	284,515	284,371	284,202	284,003	278,827	278,618	277,492	277,169	257,515	257,009	256,616	254,208	239,496	231,954	226,405	215,612	214,826	214,423	194,980	191,566
Shares Outstanding	6.0%	1,363	1,285	1,110	1,108	858	616	575	555	555	555	554	544	474	336	-	-	-	-	-	-	-
Minority Interest	0%	-138	-138	-138	-138	-133	-133	-49.00	-39.00	-19.00	103	378	1,039	1,200	827	722	1,496	1,208	621	689	-	-
Float	-	-	-	-	4,169	-	-	-	21,028	-	-	-	53,245	-	-	-	33,300	-	-	-	15,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	22.9%	-3,200	-4,151	-2,849	-4,834	-3,466	-2,356	-3,371	-3,365	-4,885	-6,660	-8,268	-6,233	-4,707	-6,751	-6,919	-7,278	-9,270	-5,012	-3,757	-4,460	-3,969
Share Based Compensation	-4.2%	138	144	162	199	212	203	314	323	260	483	354	356	325	164	500	600	772	417	1,059	389	422
Cashflow From Investing	-92.3%	4.00	52.00	5.00	-4,716	315	281	341	48.00	747	-70.00	-204	17,367	-485	2,856	-181	1,479	13,130	-7,084	-5,497	1,790	2,422
Cashflow From Financing	-	5.00	-	7.00	-	5,505	-	4,515	-	4.00	-114	21.00	-4.00	21,997	7,736	2,307	9,821	696	-28.00	15,149	6,878	-13.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RKDA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 1,255	$ 1,232
Operating expenses (income):
Cost of revenues	820	688
Research and development	272	359
Loss (Gain) on sale of property and equipment	2	(19)
Impairment of property and equipment	36	0
Selling, general and administrative	3,189	4,071
Total operating expenses	4,319	5,099
Loss from continuing operations	(3,064)	(3,867)
Interest income	45	198
Other income, net	3	32
Valuation loss on March 2023 PIPE	0	(6,076)
Change in fair value of common stock warrant and option liabilities	593	940
Issuance and offering costs allocated to liability classified options	0	(430)
Net loss from continuing operations	(2,423)	(9,203)
Net loss from discontinued operations	0	(181)
Net loss attributable to common stockholders	$ (2,423)	$ (9,384)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders from continuing operations	$ (1.78)	$ (10.65)
Diluted net loss per share attributable to common stockholders from continuing operations	(1.78)	(10.65)
Basic net loss per share attributable to common stockholders from discontinued operations	0	(0.21)
Diluted net loss per share attributable to common stockholders from discontinued operations	0	(0.21)
Net loss per basic share attributable to common stockholders	(1.78)	(10.86)
Net loss per diluted share attributable to common stockholders	$ (1.78)	$ (10.86)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	1,361,657	864,391
Weighted average shares - Diluted	1,361,657	864,391
Other comprehensive income, net of tax
Unrealized gains on available-for-sale securities	$ 60	$ 0
Other comprehensive income	60	0
Comprehensive loss attributable to common stockholders	(2,363)	(9,384)
Product
Revenues:
Total revenues	$ 1,255	$ 1,232

RKDA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,317	$ 6,518
Short-term investments	5,184	5,124
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2024 and December 31, 2023	760	514
Inventories - current	1,831	1,958
Assets held for sale	15	51
Prepaid expenses and other current assets	535	807
Total current assets	11,642	14,972
Property and equipment, net	328	384
Right of use asset	695	792
Inventories - noncurrent	3,178	3,354
Intangible assets, net	39	39
Other noncurrent assets	164	164
Total assets	16,046	19,705
Current liabilities:
Accounts payable and accrued expenses	1,732	2,410
Operating lease liability — current	801	852
Total current liabilities	2,878	3,590
Operating lease liability — noncurrent	21	155
Common stock warrant and option liabilities	664	1,257
Other noncurrent liabilities	2,000	2,000
Total liabilities	5,563	7,002
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value - 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 1,362,840 and 1,285,337 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	65	65
Additional paid-in capital	284,658	284,515
Accumulated other comprehensive income	161	101
Accumulated deficit	(274,263)	(271,840)
Total stockholders' equity	10,621	12,841
Non-controlling interest	(138)	(138)
Total stockholders' equity	10,483	12,703
Total liabilities and stockholders’ equity	16,046	19,705
Related Party [Member]
Current liabilities:
Other current liabilities	75	58
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 270	$ 270

About Arcadia Biosciences Inc

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

CEO	Mr. Stanley E. Jacot Jr.
WEBSITE	arcadiabio.com
INDUSTRY	Packaged Foods
EMPLOYEES	30

Arcadia Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Arcadia Biosciences Inc? What does RKDA stand for in stocks?

RKDA is the stock ticker symbol of Arcadia Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcadia Biosciences Inc (RKDA)?

As of Fri May 17 2024, market cap of Arcadia Biosciences Inc is 4.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RKDA stock?

You can check RKDA's fair value in chart for subscribers.

What is the fair value of RKDA stock?

You can check RKDA's fair value in chart for subscribers. The fair value of Arcadia Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcadia Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RKDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcadia Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RKDA is over valued or under valued. Whether Arcadia Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcadia Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RKDA.

What is Arcadia Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RKDA's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 0.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RKDA PE ratio will change depending on the future growth rate expectations of investors.